Article Text
Statistics from Altmetric.com
Smoking is the single most important causal risk factor for COPD. The public health campaigns and policies have worked to reduce smoking rates by over 50% since those of the 1970s and are now at an all-time low in the UK,1 Canada and throughout most of the western world. Yet, curiously and paradoxically, the burden of COPD (as measured by its prevalence, hospitalisation and mortality rate) is at an all-time high in these countries, and over the next 20 years, the burden of COPD is expected to more than double.2 Why?
The answer is a simple math issue related to ageing. Most industrialised countries of the world are getting older and, unquestionably, COPD is an age-related disorder. Whereas COPD is almost unheard of in individuals less than 40 years of age (even among heavy smokers), 1 in 10 lifetime never-smokers and 1 in 3 develop COPD by age 75.3 This notion of accelerated ageing of COPD is supported by animal models, which demonstrate premature appearance of emphysematous lungs in mice, which have genetically altered age-related pathways (eg, Klotho mice).4
Physiologically, ageing can be defined as the progressive decline in homeostasis and loss of tissue and organ functions over time.5 Ageing is a risk factor for many (non-communicable) chronic conditions beyond COPD including cancer, congestive heart failure, dementia, diabetes and osteoarthritis.5 The aetiology of ageing is unknown, but the most popular theory involves accumulation of reactive oxygen species (ROS) related to excess oxidative stress.6 At a cellular level, ageing manifests as an irreversible loss of proliferative capacity of viable mitotic cells, termed cellular senescence. Unlike apoptotic cells, senescent cells remain metabolically active and display a senescence-associated secretory phenotype characterised by the production of proinflammatory cytokines such as interleukin (IL)-6, IL-8 and matrix metalloproteinases (MMPs).7 …
Footnotes
Contributors DDS and MO contributed equally to the write-up of this editorial.
Competing interests DDS has received honoraria for speaking engagements from AstraZeneca, Novartis and Boehringer Ingelheim; has received stipends for serving on advisory boards of AstraZeneca, Regeneron, Sanofi and Boehringer Ingelheim; and received research funding from AstraZeneca, Merck and Boehringer Ingelheim. MO has no competing interests to declare.
Provenance and peer review Commissioned; externally peer reviewed.
Linked Articles
- Chronic obstructive pulmonary disease